News
Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...
Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...
Current health news highlights include UK investor backing in Assura's acquisition by PHP, Novo Nordisk's legal affairs over Wegovy drug sales, and Apollo Hospitals' increased AI investments. The CDC ...
In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...
In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...
Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...
Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.
Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...
Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...
SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results